RNA Therapeutics and Manufacturing Asia 2025 (Solution Provider)

IMAPAC Pte Ltd

This event will bring together experts, researchers, and industry leaders to explore the latest trends in RNA therapeutics and manufacturing

Amari Bangkok

The RNA therapeutics industry is poised for a transformative 2025, driven by groundbreaking technological advancements, expanding clinical applications, and a rapidly growing pipeline of innovative therapies. Following the remarkable success of mRNA-based COVID-19 vaccines, the field has seen a surge in investment and research aimed at unlocking RNA's potential for a wide range of therapeutic uses. From targeted cancer treatments to ex vivo gene therapies for rare genetic disorders, the RNA therapeutics sector is experiencing exciting developments that continue to gain momentum.  In Southeast Asia, countries like Thailand and Singapore are making significant strides in RNA drug development. For example, SSCG Cell Therapy has partnered with Singapore's Agency for Science, Technology and Research (A*STAR) to establish joint laboratories focused on cellular immunotherapies. Additionally, Arcturus Therapeutics, in collaboration with Vinbiocare (a subsidiary of Vingroup), has begun clinical trials for ARCT-154, a self-amplifying mRNA vaccine targeting COVID-19 variants. With regulatory approvals already granted in Singapore and Vietnam, Southeast Asia is emerging as a key player in advancing mRNA vaccine technology.  As advancements in RNA delivery systems, RNA modification technologies, and manufacturing processes continue to evolve, the industry is moving toward broader clinical adoption and commercialization. These innovations are enhancing the precision and efficacy of RNA-based treatments and opening new possibilities for personalized medicine and gene therapies once considered out of reach.  RNA Therapeutics and Manufacturing Asia 2025 will bring together experts, researchers, and industry leaders to explore the latest trends in RNA therapeutics and manufacturing. Discussions will cover mRNA, RNA interference (RNAi), antisense oligonucleotides, scalable manufacturing solutions, optimizing RNA synthesis, purification, and quality control, while exploring cost-effective, high-yield production technologies. With Asia emerging as a key hub for RNA innovation, this conference offers a vital platform for professionals to share insights, tackle challenges, and drive the future of RNA-based therapies.

Limited Group Packages: Buy 2 Get 3 Tickets, Buy 3 Get 5 Tickets *Contact your Sales/Marketing Representative for the discount availablity